ACM Research Cl A had its Relative Strength (RS) Rating upgraded from 86 to 91 Thursday.
IBD's unique rating tracks market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the trailing 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history shows that the stocks that go on to make the biggest gains often have an RS Rating north of 80 as they launch their largest climbs.
Here Are 3 Keys For Successful Stock Investing
ACM Research Cl A is within a buy zone after breaking past a 26.32 entry in a cup without handle. Once a stock moves 5% or higher beyond the original entry, it's considered out of buy range.
ACM Research Cl A posted 11% EPS growth in the latest quarterly report. Revenue gains came in at 21%. The company is expected to report its latest earnings and sales numbers on or around Feb. 26.
The company earns the No. 3 rank among its peers in the Electronics-Semiconductor Equipment industry group. Nova is the No. 1-ranked stock within the group.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
